In a groundbreaking discovery that challenges long-standing paradigms in cancer immunotherapy, researchers from Mass General Brigham, Dana-Farber Cancer Institute, and the Broad Institute of MIT and Harvard have identified a novel immune evasion mechanism in acute myeloid leukemia (AML) involving the glycoprotein CD43. Their research, recently published in the journal Science, provides compelling evidence that contrary to existing beliefs about the dominance of the CD47 “don’t eat me” signal, CD43 plays a far more significant role in protecting AML cells from macrophage-mediated destruction.
Macrophages, the innate immune system’s frontline phagocytes, are known for their ability to recognize and engulf malignant cells, a process often facilitated by detecting “eat me” signals expressed on tumor cell surfaces. However, tumors have evolved sophisticated mechanisms to avoid immune clearance, prominently through the expression of “don’t eat me” signals that actively inhibit phagocytosis. The canonical molecule in this context has been CD47, which binds to signal regulatory protein alpha (SIRPα) on macrophages, sending an inhibitory signal to prevent engulfment.
Despite the promising preclinical success of therapies targeting the CD47-SIRPα axis, clinical trials, particularly in hematological malignancies like AML, have yielded underwhelming outcomes. This disparity incited Dr. Jooho Chung, MD, PhD, Mounica Vallurupalli, MD, and colleagues to undertake a comprehensive genome-wide loss of function screening in AML cell lines to systematically uncover other molecular players modulating macrophage recognition and phagocytosis.
Utilizing CRISPR-Cas9 technology, the research team selectively knocked out individual genes across the AML genome and assessed the subsequent impact on macrophage detection. Unexpectedly, the impact of CD47 disruption on phagocytosis was marginal. Instead, the absence of CD43 on AML cells led to a pronounced increase in macrophage-mediated clearance. CD43, a sialoglycosylated mucin, emerged as a formidable “don’t eat me” signal, acting through its heavily sialylated glycans to establish a glyco-immune barrier that shields AML cells from immune attack.
This revelation pivots the focus onto the subtleties of glyco-immunology and emphasizes the critical role of post-translational modifications in cancer immune evasion. Sialylation, the addition of sialic acid residues to glycoproteins like CD43, appears to be instrumental in establishing a physical and biochemical shield that impairs macrophage recognition and activation. By masking or modulating surface epitopes essential for immune triggering, sialylated CD43 creates an immunosuppressive pericellular environment, effectively undermining the host’s innate immune defenses.
The implications of these findings are profound. Targeting CD43 or its sialylation patterns could represent a novel therapeutic avenue to overcome the limitations of current macrophage checkpoint blockade strategies. This approach may potentiate macrophage phagocytic activity, reengage innate anti-leukemic immunity, and ultimately improve clinical responses in AML patients who have shown resistance to CD47-directed therapies. Moreover, the broader presence of CD43 and similar glyco-immune barriers in other hematologic and solid tumors raises the possibility that this mechanism may represent a ubiquitous immune resistance strategy in cancer biology.
Mechanistically, the team delineated that CD43’s strong anti-phagocytic function is mediated through its extensive sialylation, which likely interferes with macrophage receptors that detect “eat me” signals or otherwise promote phagocytosis. This finding is consistent with emerging literature underscoring the importance of glycans in modulating immune cell interactions. The research underscores the necessity of integrating glycomics into immuno-oncology research to fully appreciate the complexities of tumor-immune interactions.
This study also highlights the importance of unbiased, high-throughput genetic screening methods to uncover unanticipated regulatory nodes in biological systems. The surprising minimal effect of CD47 ablation on macrophage recognition in AML contradicts a decade of assumption and emphasizes the heterogeneity of cancer immune evasion mechanisms, which must be carefully considered when designing therapeutic interventions. Such data advocate for a more personalized or disease-specific approach to immunotherapy.
Furthermore, the research adds a new dimension to the understanding of the bone marrow microenvironment in AML pathogenesis. Given that macrophages within the bone marrow niche play vital roles in immune surveillance, the elucidation of CD43 as a glyco-immune barrier informs future studies aiming to modulate this microenvironment to favor immune clearance of leukemic cells. Future work may explore whether sialyltransferase enzymes responsible for CD43 sialylation could serve as additional therapeutic targets.
The robust experimental design, incorporating cutting-edge genome-scale CRISPR screens and detailed glycosylation analyses, sets a new standard for investigating the molecular underpinnings of tumor immune evasion. Translational efforts spurred by these findings may involve the development of monoclonal antibodies, glycosylation inhibitors, or CAR macrophage therapies engineered to bypass or counteract CD43-mediated immune resistance.
Importantly, these findings resonate beyond AML, as glycosylated mucins are prevalent in diverse cancer types. This paradigm of a glyco-immune barrier could explain the incomplete success of current immune checkpoint inhibitors in certain malignancies and stimulate a new wave of research into glycan-targeted immunotherapies. The work heralds a new frontier in cancer immunology where the intricate dance of sugar molecules on cancer cell surfaces profoundly dictates immune outcome.
In conclusion, this seminal research redefines the landscape of macrophage checkpoint signaling in AML, shifting attention from the canonical CD47 to the dominant and previously underappreciated role of sialylated CD43. By uncovering a pivotal glyco-immune barrier, the study opens new avenues for therapeutic intervention, aiming to dismantle tumor immune evasion and improve patient prognoses in leukemia and potentially a wider spectrum of cancers.
Subject of Research: Cells
Article Title: Sialylated CD43 forms a glyco-immune barrier that restrains anti-leukemic immunity
News Publication Date: 10-Apr-2026
Web References: 10.1126/science.ady5196
Keywords: Cancer research, Immunotherapy, Acute myeloid leukemia, CD43, CD47, Macrophages, Glycosylation, Sialylation, Immune evasion, Phagocytosis, CRISPR screening, Glyco-immune barrier
